In their preliminary evaluation of a personalized neoantigen vaccine for treatment of microsatellite-stable CRC, Yu et al. recently employed IFN-γ ELISpot to evaluate neoantigen-specific T cell activity[85]. The gene discussed is IFNG; the disease is colorectal carcinoma.